Altmeyer Anne 4
4 · Corbus Pharmaceuticals Holdings, Inc. · Filed Jun 11, 2026
Research Summary
AI-generated summary of this filing
Corbus (CRBP) Director Anne Altmeyer Sells Shares
What Happened
Anne Altmeyer, a director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), sold 2,412 shares on June 10, 2026. The transactions produced approximately $19,088 in proceeds at a weighted average price of $7.91 per share; individual sale prices ranged from $7.71 to $7.97. This was a sale (disposition), not a purchase.
Key Details
- Transaction date: June 10, 2026; Form 4 filed June 11, 2026 (timely).
- Transaction type/code: Sale (S).
- Shares sold: 2,412; reported proceeds: $19,088.
- Price: weighted average $7.91; range $7.71–$7.97 (sold in multiple trades).
- Post-transaction ownership: exact post-sale total not provided here; filing notes ownership includes 3,800 unvested RSUs subject to vesting (footnote).
- Notable footnotes: sale executed under a Rule 10b5-1 trading plan adopted March 11, 2026 (F1); weighted-average price and price range disclosed, and the filer can provide a breakdown of shares at each price on request (F2); 3,800 unvested RSUs are included in reported ownership (F3).
Context
The sale was made under a prearranged Rule 10b5-1 plan, which typically means the trades were automatic per a prior plan and may not reflect the insider’s contemporaneous view of the company. This is a routine director sale of modest dollar value (~$19k) and does not by itself indicate management sentiment.
Insider Transaction Report
- Sale
Common Stock, par value $0.0001 per share
[F1][F2][F3]2026-06-10$7.91/sh−2,412$19,088→ 7,579 total
Footnotes (3)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2026.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.71 to $7.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This amount includes 3,800 unvested RSUs subject to the grant's vesting schedule as previously reported.